Godrej Ninja's new TVC celebrates the charm of the furry companions
HighlightsGodrej Pet Care, a subsidiary of Godrej Consumer Products Limited, has launched Godrej Ninja, a scientifically formulated pet food brand for dogs, starting its rollout in Tamil Nadu. The television commercial campaign for Godrej Ninja emphasizes the connection between gut health and stronger immunity in dogs, blending emotional storytelling with rational messaging. The campaign features a playful character known as the dog-doctor, designed to communicate scientific credibility in pet nutrition while maintaining warmth and charm to resonate with pet owners.
Godrej
Pet Care
, a subsidiary of Godrej Consumer Products (GCPL), has introduced
Godrej Ninja
, a pet care brand offering scientifically formulated
pet food for dogs
.
A
TVC campaign
has been launched in Tamil Nadu to support the rollout of Godrej Ninja across the state. The TVC is conceptualised and developed by Godrej Creative Lab, the in-house creative studio of GCPL.
Chirag Aga, head of marketing, Godrej Pet Care (GPC), shared, 'While Ninja is currently available only in Tamil Nadu, this campaign marks the start of our journey to spotlight the vital link between gut health and stronger immunity in dogs. Our storytelling blends scientific credibility with emotional warmth—and of course, celebrates the irresistible charm of our furry companions.'
The Godrej Ninja TVC balances
emotional storytelling
with rational messaging—anchoring on a pet dogs well-being, while subtly introducing the benefits of Ninja's nutrition.
The ad's warm, cinematic style and vernacular script enhance authenticity, building trust in a relatively new brand. The narrative's focus on 'family' and 'care' ties in seamlessly with the ethos of pet parenting, which is fast evolving across urban and semi-urban India.
The tagline 'More gut Power, Less Sick Days' reinforces nourishment and love—elements crucial in establishing a pet food brand's emotional relevance.
Shalini Avadhani and Gaurav Kumar, lead creative strategists - creative Lab, Godrej Consumer Products, commented, 'We wanted communication to reflect our expertise in
pet nutrition
, but without sounding overly clinical. That's where the idea of the dog-doctor came in a playful character with human hands to bridge scientific credibility with warmth and charm. The dog-doctor champions the idea that every dog deserves a healthy gut, and that's exactly what Godrej Ninja delivers.'
Watch the video here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
12 minutes ago
- Economic Times
Aditya Birla Capital shares up 3%; Advent International likely offloads stake in block deal
Aditya Birla Capital shares went up 3% amid reports that Advent International has offloaded a stake in a block deal. The PE firm, which invested Rs 1,000 crore in 2020 in the stock, stands to earn a 138% return. A 30-day lock-in applies to the offloaded shares. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Aditya Birla Capital Q4 earnings Aditya Birla Capital share price target and performance Tired of too many ads? Remove Ads Shares of Aditya Birla Capital jumped up to 3% to Rs 249.80 on the BSE on Wednesday, as US-based private equity firm Advent International is said to have pared its stake in the company through a block deal According to media reports, Advent affiliate Jomei Investments had planned to sell 3.6 crore shares — representing a 1.4% stake in Aditya Birla Capital — via open market transactions. The floor price for the deal was set at Rs 237.81 per share, nearly 2% below the previous NSE closing price. At this price, the deal size is estimated at around Rs 856 crore.A large block deal was observed in the counter this morning, though details of the buyers and sellers could not be independently originally invested Rs 1,000 crore in 2020 through a preferential allotment of 10 crore equity shares at Rs 100 apiece. Based on the current floor price, the firm stands to make a return of 138% on its the quarter ended 31 March 2025, Aditya Birla Capital reported a consolidated net profit of Rs 865 crore, marking a 6% year-on-year increase when adjusted for one-time gains. In Q4 FY24, the company had posted a net profit of Rs 1,245 crore, which included exceptional gains from a stake sale in its asset management business via an OFS. Excluding that, profit stood at Rs 812 income rose to Rs 12,239 crore in Q4 FY25, up from Rs 10,803 crore in the year-ago a separate statement, the company said its overall lending portfolio—including NBFC and HFC segments—grew 27% YoY to Rs 1,57,404 crore as of 31 March 2025. Total AUM across the AMC, life, and health insurance businesses rose 17% YoY to Rs 5,11,260 crore. Total premium collected from life and health insurance climbed 22% to Rs 25,579 crore in a standalone basis, profit after tax stood at Rs 654 crore in Q4 FY25, compared to Rs 616 crore a year earlier. Total income grew to Rs 3,879 crore from Rs 3,527 crore during the same to Trendlyne, the average target price for Aditya Birla Capital is Rs 254, implying an upside of around 5% from current levels. Of the 10 analysts tracking the stock, most have a 'Strong Buy' stock's Relative Strength Index (RSI) stands at 77.8, indicating overbought conditions and the potential for a pullback. The MACD is at 7.8, remaining above both its centerline and signal line—typically a bullish Birla Capital shares closed 1.04% higher at Rs 242.7 on the BSE in the previous session. The stock has gained 36% year-to-date and 54% over the past three months.
Business Upturn
13 minutes ago
- Business Upturn
KP Green Engineering secures Rs 97.27 crore orders across diverse segments
By Aman Shukla Published on June 11, 2025, 11:06 IST KP Green Engineering has announced the receipt of confirmed orders worth ₹97.27 crores from multiple clients, highlighting the company's growing footprint in the infrastructure and renewable energy sectors. These new orders span across solar projects, transmission towers, isolators, crash barriers, and rooftop installations, reflecting the company's diverse capabilities and strong market presence. The largest portion of the order comes from the crash barrier segment, valued at ₹47.83 crores, aimed at railway track fencing and related infrastructure. The solar projects segment follows with ₹37.56 crores, covering fixed tilt and tracker-type module mounting structures. Additional orders include ₹7.18 crores for transmission tower materials and substation structures, ₹0.26 crores for various isolators, and ₹4.44 crores for rooftop solutions. KP Green Engineering has set a target to complete all these projects by March 31, 2026. These significant wins underscore the company's strategic growth and its commitment to delivering high-quality engineering solutions across critical infrastructure domains. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
13 minutes ago
- Business Upturn
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025
By GlobeNewswire Published on June 11, 2025, 10:00 IST Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Halle (Saale) / Munich, Germany, June 11, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its first quarter financial results for the period ended March 31, 2025 and provide a corporate update on Tuesday, June 17, 2025. The Company will host a conference call and webcast open to the public. Conference call detailsDate: June 17, 2025 Time: 3:00 pm CEST / 9:00 am EDT The conference call will be available via phone and webcast. The live audio webcast of the call will be available on Vivoryon´s website at: To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website: It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance. ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the 'Company'), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'project,' 'predict,' 'should' and 'will' and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor Contacts Vivoryon Therapeutics Manuela Bader, Director IR & Communication Email: [email protected] LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38 Email: [email protected] Media Contact Trophic CommunicationsValeria Fisher or Verena SchossmannTel: +49 175 8041816 / +49 151 219 412 77 Email: [email protected] Attachment 20250611_Q1 2025 NoR_final Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
